About: Hydroxychloroquine in rheumatic autoimmune disorders and beyond

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine in rheumatic autoimmune disorders and beyond Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine in rheumatic autoimmune disorders and beyond
Creator	Reggiori, Fulvio Mauthe, Mario Nirk, Laura
Source	Medline; PMC
abstract	Initially used as antimalarial drugs, hydroxychloroquine (HCQ) and, to a lesser extent, chloroquine (CQ) are currently being used to treat several diseases. Due to its cost‐effectiveness, safety and efficacy, HCQ is especially used in rheumatic autoimmune disorders (RADs), such as systemic lupus erythematosus, primary Sjögren's syndrome and rheumatoid arthritis. Despite this widespread use in the clinic, HCQ molecular modes of action are still not completely understood. By influencing several cellular pathways through different mechanisms, CQ and HCQ inhibit multiple endolysosomal functions, including autophagy, as well as endosomal Toll‐like receptor activation and calcium signalling. These effects alter several aspects of the immune system with the synergistic consequence of reducing pro‐inflammatory cytokine production and release, one of the most marked symptoms of RADs. Here, we review the current knowledge on the molecular modes of action of these drugs and the circumstances under which they trigger side effects. This is of particular importance as the therapeutic use of HCQ is expanding beyond the treatment of malaria and RADs.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.15252/emmm.202012476
bibo:pmid	32715647
has license	cc-by
sha1sum (hex)	c11e80833fec065fcb96a6ae513e2f0db6cd815a
schema:url	https://doi.org/10.15252/emmm.202012476
resource representing a document's title	Hydroxychloroquine in rheumatic autoimmune disorders and beyond
has PubMed Central identifier	PMC7411564
has PubMed identifier	32715647
schema:publication	EMBO Mol Med
resource representing a document's body	covid:c11e80833fec065fcb96a6ae513e2f0db6cd815a#body_text
is schema:about of	named entity 'immune system' named entity 'expanding' named entity 'PRIMARY' named entity 'REDUCING' named entity 'CHLOROQUINE' named entity 'RELEASE' named entity 'SIDE EFFECTS' named entity 'FUNCTIONS' named entity 'TREATMENT OF MALARIA' named entity 'UNDERSTOOD' named entity 'MOLECULAR' named entity 'DUE TO' named entity 'THERAPEUTIC USE' named entity 'MECHANISMS' named entity 'KNOWLEDGE' named entity 'SYMPTOMS' named entity 'CYTOKINE PRODUCTION' named entity 'extent' named entity 'Due' named entity 'activation' named entity 'Here' named entity 'completely' named entity 'treat' named entity 'modes' named entity 'Sjögren's syndrome' named entity 'cost-effectiveness' named entity 'HCQ' named entity 'RADs' named entity 'RADs' named entity 'pro-inflammatory cytokine' named entity 'HCQ' named entity 'antimalarial drugs' named entity 'Hydroxychloroquine' named entity 'trans-Golgi network' named entity 'cytoplasmic' named entity 'pathogenesis' named entity 'Tumour' named entity 'type I IFN' named entity 'cytokines' named entity 'IL-23' named entity 'HCQ' named entity 'endosomal' named entity 'Th17' named entity 'macroautophagy' named entity 'autoimmune diseases' named entity 'intracellular' named entity 'CXCR4' named entity 'cell surface' named entity 'endosomes' named entity 'CD154' named entity 'visual impairments' named entity 'systemic lupus erythematosus' named entity 'cellular levels' named entity 'TCRs' named entity 'gastric cancer' named entity 'pro-inflammatory cytokines' named entity 'APCs' named entity 'HCQ' named entity 'metastasis' named entity 'endosomes' named entity 'cancer cell' named entity 'HCQ' named entity 'tumour' named entity 'SLE' named entity 'T-cell' named entity 'viruses' named entity 'dermatological' named entity 'receptor' named entity 'hydroxychloroquine sulphate' named entity 'saliva production' named entity 'saliva production' named entity 'TLR' named entity 'IL-15' named entity 'macrophages' named entity 'autoantibodies' named entity 'TLRs' named entity 'organismal' named entity 'antigen presentation' named entity 'excreted'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software